Effects of clomiphene citrate and leuprolide acetate on luteal-phase hyperprolactinemia during ovarian stimulation with menopausal gonadotropins

Carolyn R. Kaplan, Mi Kyoung Koong, David L. Olive, Robert M. Riehl, William N. Burns, Terry R. Groff, Robert S Schenken

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hyperprolactinemia, a known modulator of reproductive function, occurs commonly in women undergoing ovarian stimulation with human menopausal gonadotropins (hMG). Clomiphene citrate (CC) and gonadotropin releasing hormone analogues (GnRHa), when administered during the luteal phase, attenuate the hyperprolactinemic response to hMG. We asked whether follicular-phase administration of CC and GnRHa, as employed clinically in women undergoing ovarian stimulation for in vitro fertilization or gamete intrafallopian transfer, would alter the incidence and severity of hMG-induced luteal-phase hyperprolactinemia. Seventy-five percent of all patients had at least one luteal prolactin level >25 ng/ml, and 40% had mean luteal-phase prolactin levels >25 ng/ml. The incidence of hyperprolactinemia was similar in pregnant and nonpregnant cycles. The incidence of hyperprolactinemia was similar for both the GnRH agonist-treated group and those given clomiphene citrate. The increase in mean luteal prolactin levels over the follicular-phase baseline level was significantly greater in the CC-treated group (P=0.03). This was due to the significant suppression of follicular-phase baseline prolactin levels in patients receiving CC. We conclude that neither CC nor GnRHa administration in the follicular phase prevents lutealphase hyperprolactinemia in women undergoing ovarian stimulation with hMG.

Original languageEnglish (US)
Pages (from-to)308-313
Number of pages6
JournalJournal of in Vitro Fertilization and Embryo Transfer
Volume8
Issue number6
DOIs
StatePublished - Dec 1991

Fingerprint

Leuprolide
Menotropins
Clomiphene
Hyperprolactinemia
Ovulation Induction
Luteal Phase
Follicular Phase
Gonadotropin-Releasing Hormone
Prolactin
Corpus Luteum
Incidence
Gamete Intrafallopian Transfer
Fertilization in Vitro

Keywords

  • clomiphene citrate
  • gonadotropin releasing hormone analogues (GnRHa)
  • hyperprolactinemia
  • ovarian stimulation

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Embryology
  • Developmental Biology

Cite this

Effects of clomiphene citrate and leuprolide acetate on luteal-phase hyperprolactinemia during ovarian stimulation with menopausal gonadotropins. / Kaplan, Carolyn R.; Koong, Mi Kyoung; Olive, David L.; Riehl, Robert M.; Burns, William N.; Groff, Terry R.; Schenken, Robert S.

In: Journal of in Vitro Fertilization and Embryo Transfer, Vol. 8, No. 6, 12.1991, p. 308-313.

Research output: Contribution to journalArticle

Kaplan, Carolyn R. ; Koong, Mi Kyoung ; Olive, David L. ; Riehl, Robert M. ; Burns, William N. ; Groff, Terry R. ; Schenken, Robert S. / Effects of clomiphene citrate and leuprolide acetate on luteal-phase hyperprolactinemia during ovarian stimulation with menopausal gonadotropins. In: Journal of in Vitro Fertilization and Embryo Transfer. 1991 ; Vol. 8, No. 6. pp. 308-313.
@article{b3aa55a5761c471bb7be663898218244,
title = "Effects of clomiphene citrate and leuprolide acetate on luteal-phase hyperprolactinemia during ovarian stimulation with menopausal gonadotropins",
abstract = "Hyperprolactinemia, a known modulator of reproductive function, occurs commonly in women undergoing ovarian stimulation with human menopausal gonadotropins (hMG). Clomiphene citrate (CC) and gonadotropin releasing hormone analogues (GnRHa), when administered during the luteal phase, attenuate the hyperprolactinemic response to hMG. We asked whether follicular-phase administration of CC and GnRHa, as employed clinically in women undergoing ovarian stimulation for in vitro fertilization or gamete intrafallopian transfer, would alter the incidence and severity of hMG-induced luteal-phase hyperprolactinemia. Seventy-five percent of all patients had at least one luteal prolactin level >25 ng/ml, and 40{\%} had mean luteal-phase prolactin levels >25 ng/ml. The incidence of hyperprolactinemia was similar in pregnant and nonpregnant cycles. The incidence of hyperprolactinemia was similar for both the GnRH agonist-treated group and those given clomiphene citrate. The increase in mean luteal prolactin levels over the follicular-phase baseline level was significantly greater in the CC-treated group (P=0.03). This was due to the significant suppression of follicular-phase baseline prolactin levels in patients receiving CC. We conclude that neither CC nor GnRHa administration in the follicular phase prevents lutealphase hyperprolactinemia in women undergoing ovarian stimulation with hMG.",
keywords = "clomiphene citrate, gonadotropin releasing hormone analogues (GnRHa), hyperprolactinemia, ovarian stimulation",
author = "Kaplan, {Carolyn R.} and Koong, {Mi Kyoung} and Olive, {David L.} and Riehl, {Robert M.} and Burns, {William N.} and Groff, {Terry R.} and Schenken, {Robert S}",
year = "1991",
month = "12",
doi = "10.1007/BF01133019",
language = "English (US)",
volume = "8",
pages = "308--313",
journal = "Journal of Assisted Reproduction and Genetics",
issn = "1058-0468",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Effects of clomiphene citrate and leuprolide acetate on luteal-phase hyperprolactinemia during ovarian stimulation with menopausal gonadotropins

AU - Kaplan, Carolyn R.

AU - Koong, Mi Kyoung

AU - Olive, David L.

AU - Riehl, Robert M.

AU - Burns, William N.

AU - Groff, Terry R.

AU - Schenken, Robert S

PY - 1991/12

Y1 - 1991/12

N2 - Hyperprolactinemia, a known modulator of reproductive function, occurs commonly in women undergoing ovarian stimulation with human menopausal gonadotropins (hMG). Clomiphene citrate (CC) and gonadotropin releasing hormone analogues (GnRHa), when administered during the luteal phase, attenuate the hyperprolactinemic response to hMG. We asked whether follicular-phase administration of CC and GnRHa, as employed clinically in women undergoing ovarian stimulation for in vitro fertilization or gamete intrafallopian transfer, would alter the incidence and severity of hMG-induced luteal-phase hyperprolactinemia. Seventy-five percent of all patients had at least one luteal prolactin level >25 ng/ml, and 40% had mean luteal-phase prolactin levels >25 ng/ml. The incidence of hyperprolactinemia was similar in pregnant and nonpregnant cycles. The incidence of hyperprolactinemia was similar for both the GnRH agonist-treated group and those given clomiphene citrate. The increase in mean luteal prolactin levels over the follicular-phase baseline level was significantly greater in the CC-treated group (P=0.03). This was due to the significant suppression of follicular-phase baseline prolactin levels in patients receiving CC. We conclude that neither CC nor GnRHa administration in the follicular phase prevents lutealphase hyperprolactinemia in women undergoing ovarian stimulation with hMG.

AB - Hyperprolactinemia, a known modulator of reproductive function, occurs commonly in women undergoing ovarian stimulation with human menopausal gonadotropins (hMG). Clomiphene citrate (CC) and gonadotropin releasing hormone analogues (GnRHa), when administered during the luteal phase, attenuate the hyperprolactinemic response to hMG. We asked whether follicular-phase administration of CC and GnRHa, as employed clinically in women undergoing ovarian stimulation for in vitro fertilization or gamete intrafallopian transfer, would alter the incidence and severity of hMG-induced luteal-phase hyperprolactinemia. Seventy-five percent of all patients had at least one luteal prolactin level >25 ng/ml, and 40% had mean luteal-phase prolactin levels >25 ng/ml. The incidence of hyperprolactinemia was similar in pregnant and nonpregnant cycles. The incidence of hyperprolactinemia was similar for both the GnRH agonist-treated group and those given clomiphene citrate. The increase in mean luteal prolactin levels over the follicular-phase baseline level was significantly greater in the CC-treated group (P=0.03). This was due to the significant suppression of follicular-phase baseline prolactin levels in patients receiving CC. We conclude that neither CC nor GnRHa administration in the follicular phase prevents lutealphase hyperprolactinemia in women undergoing ovarian stimulation with hMG.

KW - clomiphene citrate

KW - gonadotropin releasing hormone analogues (GnRHa)

KW - hyperprolactinemia

KW - ovarian stimulation

UR - http://www.scopus.com/inward/record.url?scp=0025748084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025748084&partnerID=8YFLogxK

U2 - 10.1007/BF01133019

DO - 10.1007/BF01133019

M3 - Article

C2 - 1770270

AN - SCOPUS:0025748084

VL - 8

SP - 308

EP - 313

JO - Journal of Assisted Reproduction and Genetics

JF - Journal of Assisted Reproduction and Genetics

SN - 1058-0468

IS - 6

ER -